Comparison
Omega-3 (EPA/DHA) vs TUDCA
Side-by-side of Omega-3 (EPA/DHA) and TUDCA. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Omega-3 (EPA/DHA)
Omega 3 fish oil profile: EPA/DHA marine fatty acids, 2-4 g/day cuts triglycerides 20-30%, REDUCE-IT showed 25% cardiovascular risk reduction on icosapent eth.
TUDCA
TUDCA is the taurine-conjugated form of ursodeoxycholic acid, a bile-acid molecule with replicated effects on liver function, ER stress, and bile flow.
Effects at a glance
Omega-3 (EPA/DHA)
- •Reduces fasting triglycerides 20-50% at 2-4 g/day in hypertriglyceridemic patients
- •REDUCE-IT showed 25% relative risk reduction in major CV events at 4 g/day icosapent ethyl
- •Modest antidepressant effect (SMD ~0.40) for EPA-dominant formulations at 1-2 g/day
- •Atrial fibrillation incidence rises ~30-50% at 4 g/day; relevant for older patients with pre-existing CV disease
- •Tissue omega-3 index (RBC EPA + DHA) target ~8%; Western baseline typically 4-5%
- •Triglyceride and re-esterified triglyceride forms absorb ~70% better than ethyl esters in fasted state
TUDCA
- •Bile-acid molecule (taurine-conjugated UDCA) with chemical chaperone activity at the endoplasmic reticulum
- •Established pharmaceutical use for cholestasis and primary biliary cholangitis at 500-750 mg/day
- •Reduces ER stress and stabilizes misfolded proteins; the mechanistic basis for emerging ALS / retinal applications
- •Modest improvements in NAFLD markers and insulin sensitivity at 500-1,750 mg/day in small trials
- •Mitochondrial protection signal in animal models drives the longevity-supplement positioning
- •Generally well-tolerated; mild GI effects are the main dose-dependent issue
Side-by-side
| Attribute | Omega-3 (EPA/DHA) | TUDCA |
|---|---|---|
| Category | supplement | supplement |
| Also known as | fish oil, EPA, DHA, marine omega-3 | tauroursodeoxycholic acid, taurine-conjugated UDCA |
| Half-life (hr) ↗ | 48 | 4 |
| Typical dose (mg) ↗ | 2000 | 500 |
| Dosing frequency | 1 to 2 times daily with food | daily, divided into 2 doses with food |
| Routes | oral | oral |
| Onset (hr) | 4 | 1 |
| Peak (hr) | 12 | 2 |
| Molecular weight | 302.45 | 499.7 |
| Molecular formula | C20H30O2 (EPA); C22H32O2 (DHA) | C26H45NO6S |
| Mechanism | Substitutes arachidonic acid in membrane phospholipids, shifting eicosanoid production toward less-inflammatory 3-series prostaglandins and 5-series leukotrienes. Activates PPAR-alpha to lower hepatic VLDL/triglyceride synthesis. DHA modulates synaptic membrane fluidity and neuronal function. | Bile-acid signaling via FXR/TGR5 receptors; chemical chaperone reducing ER stress and unfolded protein response; mitochondrial protection through reduced outer-membrane permeabilization. |
| Legal status | Dietary supplement; prescription forms (icosapent ethyl, omega-3 acid ethyl esters) for severe hypertriglyceridemia | OTC dietary supplement (US); pharmaceutical in Italy and several Asian countries |
| WADA status | allowed | allowed |
| DEA / Rx | Not scheduled | OTC supplement |
| Pregnancy | Recommended at 200 to 600 mg DHA/day for fetal development | Insufficient data for supplement use; UDCA used in cholestasis of pregnancy |
| CAS | 10417-94-4 | 14605-22-2 |
| PubChem CID | 446284 | 9848818 |
| Wikidata | Q207688 | Q418751 |
Safety profile
Omega-3 (EPA/DHA)
Common side effects
- fishy aftertaste
- eructation (fish burps)
- mild dyspepsia
- loose stools at high doses
Contraindications
- fish allergy (use algal omega-3 alternative)
- active bleeding disorders
- scheduled surgery (discontinue 5-7 days prior)
Interactions
- warfarin and DOACs: additive antiplatelet effect at 2+ g/day; meaningful bleeding risk(moderate)
- aspirin and antiplatelet agents: additive bleeding risk at high doses(moderate)
- statins: complementary cardiovascular effects; no pharmacokinetic interaction(minor)
- antiarrhythmics: high-dose omega-3 increases AF risk; relevant in pre-existing arrhythmia(moderate)
TUDCA
Common side effects
- mild GI upset
- diarrhea (dose-dependent)
- constipation (rare)
- nausea
Contraindications
- complete biliary obstruction
- pregnancy / lactation (insufficient supplement-dose data)
- active GI disease without medical supervision
Interactions
- cyclosporine, oral contraceptives, fat-soluble vitamins: modest absorption changes via altered bile-acid pool(minor)
- phenylbutyrate: synergistic for ALS use (Relyvrio combination); consult clinician(moderate)
Which Should You Take?
Omega-3 (EPA/DHA) and TUDCA score evenly on the criteria we weight (goal breadth, legal accessibility, evidence depth). The conditionals below should drive the decision more than any aggregate score.
- → If your priority is cardiovascular health, pick Omega-3 (EPA/DHA).
- → If your priority is focus or working memory, pick Omega-3 (EPA/DHA).
- → If your priority is liver function, pick TUDCA.
- → If your priority is mitochondrial function, pick TUDCA.
Edge case: Half-lives differ materially (Omega-3 (EPA/DHA) ~48 hr vs TUDCA ~4 hr). Omega-3 (EPA/DHA) reaches steady state faster; TUDCA is easier to dial in if tolerability is uncertain.
Default choice: either is defensible. Omega-3 (EPA/DHA) edges out on goal breadth + legal accessibility; TUDCA is the right call if your priority sits in the goals listed above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Omega-3 (EPA/DHA) and TUDCA?
Omega-3 (EPA/DHA) and TUDCA differ in category (supplement vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Omega-3 (EPA/DHA) or TUDCA?
Omega-3 (EPA/DHA) half-life is 48 hours; TUDCA half-life is 4 hours.
Can you stack Omega-3 (EPA/DHA) with TUDCA?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper